News and Updates

iVeena enters into a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS) that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus. As part of the agreement, Glaukos paid $10 Million upfront and will assume all costs associated with development and regulatory activities on IVMED-80. In addition, deal terms…
SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems (iVeena), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, announces successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for a novel pharmacologic treatment of pediatric myopia.…
April 27, 2021 – Salt Lake City, UT – iVeena, a clinical stage ophthalmology company addressing unmet medical need in the pharmacologic treatment of corneal dystrophies and myopic conditions, announced today that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for its application (App.…
Dr. Karpecki is an internationally recognized opinion leader in the optometry field.
Dr. Sarah Molokhia, PI for a SBIR Phase 2 grant and Adjunct Assistant Professor at Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah and iVeena is pleased to announce that it has received a $1.68 M in Federal government grants for its keratoconus orphan drug candidate. Keratoconus…
SALT LAKE CITY--(BUSINESS WIRE)--iVeena is pleased to announce the topline results of its recently completed Phase 1/2a clinical trial, “A Randomized, Double-Masked, Trial of IVMED-80 Eyedrops for Treatment of Keratoconus.” The study objective was to determine whether a 6 or 16-week course of twice-daily IVMED-80 eyedrops (vs. placebo) could flatten…
https://millennialeye.com/articles/july-aug-20/the-innovators-experience/?single=true
iVeena, a clinical stage biopharmaceutical company with products in development for unmet needs in ophthalmology, announces the successful completion of the Series B preferred stock bridge round. The company was also awarded with a SBIR Phase II grant award from the National Eye Institute (NEI) of the National Institutes of…
Dr. Shojaei was the Vice President and Therapeutic Area (TA) Head in Ophthalmology at Shire/Takeda. He oversaw all aspects of clinical stage ophthalmic pipeline assets. Most recently, Amir's team brought Xiidra® (lifitegrast) from development to U.S. NDA filing and approval. Amir’s active engagement in the clinical development around design and…
Dr. Hu is a leading private practitioner with a keen interest in academic and research endeavors. He is a partner and owner of Texas Eye and Laser Center, an internationally recognized center of excellence, and a co-founder of Texas Eye and Laser Center. Dr. Jerry Hu completed a fellowship in…
Dr. Thompson is an internationally recognized specialist in Laser Vision Correction and Advanced Cataract Surgery. Vance Thompson, MD is an internationally recognized specialist in Laser Vision Correction and Advanced Cataract Surgery. He is the Founder of Vance Thompson Vision Sioux Falls, SD  and the Director of Refractive Surgery he also…
iVeena announces the appointment of Robert Dempsey, Group Vice President and Head of the Global Ophthalmology Franchise at Takeda (formerly Shire) to the iVeena Board of Directors. “Mr. Dempsey will add considerable ophthalmology sector expertise to the iVeena team at a critical time in the development of the company as…
iVeena receives top award at the American Society of Cataract and Refractive Surgeons At the May 4, 2019 American Society of Cataract and Refractive Surgeons, Dr. Ambati (iVeena President and Founder) presented the iVeena products in development at the inaugural Winning Pitch Challenge. The Challenge was chaired by prominent Key Opinion leaders…
iVeena announces the commencement of a 36 patient Phase I/2a pilot clinical study for the treatment of Keratoconus (IVMED-80). The Company has Orphan Drug Designation for this product.
iVeena announces the first close for its $2.75M Series B financing by Mountain Pacific Venture Fund, a health care/biotech focused venture fund.
Salt Lake City, Utah,--(BUSINESS WIRE)--iVeena Delivery Systems (iVeena), a biopharmaceutical company that develops innovative ophthalmology products, today announced that the United States Patent and Trademark Office (USPTO) communicated a notice of allowance for a patent assigned to the University of Utah and licensed to iVeena Delivery Systems Inc.
iVeena announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IVMED-80, for the treatment of keratoconus. Keratoconus is a degenerative disorder causing a cornea to become conical in shape that can seriously distort vision. This may lead to a corneal transplant. IVMED-80 is the…
iVeena Completes Phase 1/2a Pilot Clinical Study for IVMED-10, a Bioerodable, Sustained Release, Intracapsular Implant that Delivers Dexamethasone to Both Anterior and Posterior Eye Segments to Treat Inflammation and Pain Associated with Cataract Surgery.
Page 1 of 2